TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 35091443
Drug: Ceritinib 750
Normalized name: Ceritinib
DrugBank: Ceritinib (DB09063)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Ceritinib 750 mg once daily (fasted condition) in arm 1 (prior radiotherapy/ALKi-pretreated)
Study: 35091443
Drug: Ceritinib 750
Normalized name: Ceritinib
DrugBank: Ceritinib (DB09063)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Ceritinib 750 mg once daily (fasted condition) in arm 2 (no radiotherapy/ALKi-pretreated)
Study: 35091443
Drug: Ceritinib 750
Normalized name: Ceritinib
DrugBank: Ceritinib (DB09063)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Ceritinib 750 mg once daily (fasted condition) in arm 3 (prior radiotherapy/ALKi-naïve)
Study: 35091443
Drug: Ceritinib 750
Normalized name: Ceritinib
DrugBank: Ceritinib (DB09063)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Ceritinib 750 mg once daily (fasted condition) in arm 4 (no radiotherapy/ALKi-naïve)
Study: 35091443
Drug: Ceritinib 750
Normalized name: Ceritinib
DrugBank: Ceritinib (DB09063)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Ceritinib 750 mg once daily (fasted condition) in arm 5 (patients with leptomeningeal carcinomatosis)
Study: 35091462
Drug: Biological disease-modifying
Approvals — FDA: no, EMA: no, PMDA: no
Description: Biological disease-modifying drugs
Study: 35091711
Drug: Apalutamide 240
Normalized name: apalutamide 240 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Apalutamide 240 mg once-daily for 12 weeks
Study: 35092583
Drug: AMG 986
Normalized name: AMG 108
DrugBank: AMG 108 (DB05545)
Approvals — FDA: no, EMA: no, PMDA: no
Description: AMG 986 200 mg
Study: 35093104
Drug: Audit-and-feedback intervention
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Audit-and-feedback intervention including reports on antibiotic harms, stakeholder engagement, patient and provider education, identification of local champions, and blended facilitation.
Study: 35093147
Drug: Enzyme replacement
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enzyme replacement therapy (ERT) for fetuses with LSDs
Study: 35093147
Drug: Fetal gene
Normalized name: Dna Plasmid Expressing Diphtheria Toxin Triggered By The Presence Of Oncofetal Gene H19
DrugBank: Inodiftagene vixteplasmid (DB16017)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fetal gene therapy trial
Study: 35093163
Drug: Recombinant human
Normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Recombinant human growth hormone (rhGH) administered once daily for 12 weeks.
Study: 35093164
Drug: Extended-release buprenorphine
Normalized name: Buprenorphine Extended-Release Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extended-release buprenorphine (XRB)
Study: 35093737
Drug: Multimodal pelvic
Normalized name: Sus scrofa renal pelvis preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multimodal pelvic floor physiotherapy treatment (12 weekly sessions)
Study: 35093737
Drug: Multimodal pelvic
Normalized name: Sus scrofa renal pelvis preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multimodal pelvic floor physiotherapy treatment
Study: 35093998
Drug: Valganciclovir treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Valganciclovir treatment
Study: 35094896
Drug: Stockholm3 test
Normalized name: mumps skin test antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stockholm3 test with MRI and PSA ≥2 ng/ml
Study: 35095867
Drug: Trastuzumab with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trastuzumab with neoadjuvant chemotherapy
Study: 35097222
Drug: Azithromycin and
Normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Azithromycin and cefixime combination
Study: 35098120
Drug: Improvisational dance
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Improvisational dance intervention (met twice weekly for 60 min for 8 weeks)
Study: 35098170
Drug: Abiraterone acetate
Normalized name: ABIRATERONE ACETATE
DrugBank: Abiraterone (DB05812)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Abiraterone acetate plus prednisone (AAP) with androgen deprivation therapy (ADT)
Study: 35098333
Drug: Bortezomib treatment
Normalized name: Bortezomib
DrugBank: Bortezomib (DB00188)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Bortezomib treatment (neurotoxic drug)
Study: 35098345
Drug: Cetuximab (administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cetuximab (administered every 3 weeks, maximum of six doses) plus autologous expanded NK cells (infused the day after cetuximab administration)
Study: 35099278
Drug: Loop, an
Approvals — FDA: no, EMA: no, PMDA: no
Description: Loop, an Open-Source Automated Insulin Delivery System
Study: 35099783
Drug: Non-PCI treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-PCI treatment pathway (control)
Study: 35100081
Drug: Medications for
Normalized name: Medicated Shampoo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medications for opioid use disorder
Study: 35100339
Drug: Langerhans-type dendritic
Normalized name: collagen type I
Approvals — FDA: no, EMA: no, PMDA: no
Description: Langerhans-type dendritic cells (LCs) electroporated with CT7, MAGE-A3, and WT1 mRNA, 9 × 10^6 cells, administered as a priming immunization plus 2 boosters at 12, 30, and 90 days after ASCT.
Study: 35100339
Drug: Standard lenalidomide
Normalized name: Lenalidomide
DrugBank: Lenalidomide (DB00480)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Standard lenalidomide maintenance therapy started at 3 months after ASCT for all patients.
Study: 35100411
Drug: Hyperferritinemia (≥500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hyperferritinemia (≥500 ng/mL) in 46 patients (26%)
Study: 35100411
Drug: Hyperferritinemia (≥250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hyperferritinemia (≥250 ng/mL) in 90 patients (52%)
Study: 35100411
Drug: Age- and
Normalized name: AGS-499
DrugBank: AGS-499 (DB18058)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Age- and sex-matched controls without infection, n = 50, median ferritin level 102.8 ng/mL (IQR 53.5-185.7)
Study: 35101049
Drug: Cabazitaxel 20
Normalized name: cabazitaxel 20 mg/mL intravenous solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cabazitaxel 20 mg/sqm
Study: 35101049
Drug: Cabazitaxel 25
Normalized name: Cabazitaxel
DrugBank: Cabazitaxel (DB06772)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cabazitaxel 25 mg/sqm
Study: 35101049
Drug: Cabazitaxel (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cabazitaxel (20 or 25 mg/sqm)
Study: 35101175
Drug: Multi-lipid lowering
Normalized name: guggul lipids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multi-lipid lowering therapies (LLT)
Study: 35103026
Drug: Platelet-rich plasma
Normalized name: PLATELET-RICH PLASMA, AUTOLOGOUS
DrugBank: Platelet Rich Plasma (DB19295)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Platelet-rich plasma (PRP) administration
Study: 35105522
Drug: Heartech left
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heartech left ventricular partitioning device (LVPD) therapy
Study: 35105587
Drug: ACL repair
Normalized name: hyaluronic acid Ophthalmic Gel [Optimend Corneal Repair]
Approvals — FDA: no, EMA: no, PMDA: no
Description: ACL repair and InternalBrace augmentation
Study: 35105633
Drug: Celecoxib as
Normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Celecoxib as an adjunct to treatment-as-usual
Study: 35105633
Drug: Placebo as
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo as an adjunct to treatment-as-usual
Study: 35105642
Drug: Capillary blood
Normalized name: Capillary blood
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capillary blood sample antibody POCT targeting IgM and IgG against the receptor-binding domain of SARS-CoV-2
Study: 35105722
Drug: Intravenous 120
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous 120 mg belimumab
Study: 35106698
Drug: Levodopa/carbidopa treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levodopa/carbidopa treatment in 5 patients with dystonia
Study: 35106962
Drug: Isatuximab monotherapy
Normalized name: Isatuximab
DrugBank: Isatuximab (DB14811)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Isatuximab monotherapy
Study: 35107750
Drug: Droxidopa (100-600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Droxidopa (100-600 mg, 3 times daily)
Study: 36849838
Drug: Inactivated COVID-19
Normalized name: covid-19, protein subunit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inactivated COVID-19 vaccine
Study: 35108379
Drug: DMARDs (Disease-Modifying
Approvals — FDA: no, EMA: no, PMDA: no
Description: DMARDs (Disease-Modifying Anti-Rheumatic Drugs)
Study: 35110167
Drug: Group art
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group art therapy using clay (6 sessions of 1.5 hours each)
Study: 35110356
Drug: PSMA×CD3 bispecific
Approvals — FDA: no, EMA: no, PMDA: no
Description: PSMA×CD3 bispecific antibody (bsAb)
Study: 35110417
Drug: Imatinib 400
Normalized name: imatinib 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Imatinib 400 mg daily with binimetinib 45 mg twice daily
Study: 35111295
Drug: Switching to
Normalized name: Wong To Yick
Approvals — FDA: no, EMA: no, PMDA: no
Description: Switching to aripiprazole with 2-week dual administration and tapering off original agents (fast: n=38, slow: n=41)
Study: 35111295
Drug: Baseline chlorpromazine
Normalized name: Chlorpromazine
DrugBank: Chlorpromazine (DB00477)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Baseline chlorpromazine equivalent dose in ARE+ group (405.8 ± 225.8 mg)
Study: 35111828
Drug: Medical treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medical treatment with LVEF ≤55%
Study: 35112104
Drug: Pharmaceutical venous
Normalized name: bushmaster venom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmaceutical venous thromboembolism (pVTE) prophylaxis
Study: 35112299
Drug: Dienogest therapy
Normalized name: Dienogest
DrugBank: Dienogest (DB09123)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Dienogest therapy
Study: 35112382
Drug: Fuzuloparib (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fuzuloparib (150 mg single dose)
Study: 35112928
Drug: Pcrit measurement
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pcrit measurement during drug-induced sleep endoscopy (DISE)
Study: 35113285
Drug: Sym013 at
Normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sym013 at 4 mg/kg once-weekly (changed to biweekly due to adverse events)
Study: 35113285
Drug: Sym013 at
Normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sym013 at 15 mg/kg biweekly (Q2W)
Study: 35113285
Drug: Sym013 (various
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sym013 (various doses)
Study: 35113363
Drug: Etanercept (ETN)
Normalized name: Etanercept
DrugBank: Etanercept (DB00005)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Etanercept (ETN) treatment for rheumatoid arthritis
Study: 35113812
Drug: Fresolimumab (TGF-β
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fresolimumab (TGF-β neutralizing antibody)
Study: 35113934
Drug: Interferon-γ (IFN-γ)
Normalized name: Interferon Gamma
DrugBank: Interferon Gamma (DB15753)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interferon-γ (IFN-γ) administration
Study: 35114169
Drug: Pembrolizumab 200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pembrolizumab 200 mg intravenously every 3 weeks for 2 years or until disease progression
Study: 35114404
Drug: Drugs suspected
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Drugs suspected of inducing APS (14 drugs identified)
Study: 35114814
Drug: 1-month dual
Normalized name: miconazole
DrugBank: Miconazole (DB01110)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 1-month dual antiplatelet therapy after Synergy bioresorbable-polymer everolimus-eluting stent implantation
Study: 35115195
Drug: AKS-452 22.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: AKS-452 22.5 µg
Study: 35115195
Drug: AKS-452 45
Approvals — FDA: no, EMA: no, PMDA: no
Description: AKS-452 45 µg
Study: 35115195
Drug: AKS-452 90
Approvals — FDA: no, EMA: no, PMDA: no
Description: AKS-452 90 µg
Study: 35115195
Drug: AKS-452 (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: AKS-452 (all doses)
Study: 35118382
Drug: Gliadel 7.7
Normalized name: Gliadel 7.7mg Wafer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gliadel 7.7 mg implant (up to 8 wafers, 61.6 mg of carmustine)
Study: 35118382
Drug: Gliadel 7.7
Normalized name: Gliadel 7.7mg Wafer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gliadel 7.7 mg implant
Study: 35118821
Drug: Enzalutamide 160
Normalized name: Enzalutamide
DrugBank: Enzalutamide (DB08899)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Enzalutamide 160 mg once daily from day 8 to day 71
Study: 35119037
Drug: Triptorelin 3.75
Normalized name: triptorelin 3.75 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triptorelin 3.75 mg once every 28 days for up to 24 weeks after conservative surgery for DIE
Study: 35120446
Drug: First-line anti-TNF
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: First-line anti-TNF therapy for UC
Study: 35120446
Drug: First-line anti-TNF
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: First-line anti-TNF therapy for CD
Study: 35120446
Drug: First-line anti-TNF
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: First-line anti-TNF therapy for both UC and CD
Study: 35120987
Drug: Treatment of
Normalized name: DRUGS FOR TREATMENT OF LEPRA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment of primary ciliary dyskinesia pulmonary exacerbations
Study: 35121676
Drug: Cognitive Behavioral
Normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive Behavioral Therapy for Insomnia (CBT-I) delivered via telehealth, four-session protocol, details on dosage and duration not specified.
Study: 35121899
Drug: Anti-CD20 treatment
Normalized name: Allogeneic anti-CD20 CAR T cells
DrugBank: PBCAR20A (DB17189)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anti-CD20 treatment
Study: 35121950
Drug: ctDNA clearance
Normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ctDNA clearance during treatment
Study: 35122060
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of radiation, ipilimumab, and nivolumab
Study: 35122371
Drug: Endovascular thrombectomy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endovascular thrombectomy (EVT) with intravenous thrombolysis (IVT)
Study: 35122700
Drug: LY2780301 plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: LY2780301 plus weekly paclitaxel
Study: 35123460
Drug: Three-dimensional corrective
Normalized name: three-lobe sage extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Three-dimensional corrective exercise therapy (TDCET)
Study: 35123460
Drug: Generalized exercise
Normalized name: celecoxib
DrugBank: Celecoxib (DB00482)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Generalized exercise therapy (Control Group)
Study: 35123583
Drug: Enhanced cognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enhanced cognitive behavioral therapy (CBT-E), 40 sessions
Study: 35123640
Drug: Steroids-Ruxolitinib
Approvals — FDA: no, EMA: no, PMDA: no
Description: Steroids-Ruxolitinib
Study: 35123771
Drug: Navitoclax (ABT-737
Approvals — FDA: no, EMA: no, PMDA: no
Description: Navitoclax (ABT-737 analogue) monotherapy at 150 mg daily for 7-14 days, then increased to 250 mg daily
Study: 35123771
Drug: Navitoclax (ABT-737
Approvals — FDA: no, EMA: no, PMDA: no
Description: Navitoclax (ABT-737 analogue) monotherapy
Study: 35124411
Drug: Platinum doublet
Normalized name: platinum
DrugBank: Platinum (DB12257)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Platinum doublet cytotoxic chemotherapy ± immunotherapy (Cohort 2)
Study: 35124411
Drug: Post-treatment samples
Normalized name: hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Post-treatment samples (all cohorts)
Study: 35125401
Drug: Everolimus (2L
Approvals — FDA: no, EMA: no, PMDA: no
Description: Everolimus (2L targeted therapy)
Study: 35125401
Drug: Axitinib (2L
Approvals — FDA: no, EMA: no, PMDA: no
Description: Axitinib (2L targeted therapy)
Study: 35125401
Drug: Sunitinib (1L
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sunitinib (1L targeted therapy)
Study: 35126362
Drug: mRNA-1273 at
Normalized name: MRNA-1273 SARS-COV-2
DrugBank: Moderna COVID-19 Vaccine (DB15654)
Approvals — FDA: no, EMA: no, PMDA: no
Description: mRNA-1273 at a dose of 25 μg
Study: 35126362
Drug: mRNA-1273 at
Normalized name: MRNA-1273 SARS-COV-2
DrugBank: Moderna COVID-19 Vaccine (DB15654)
Approvals — FDA: no, EMA: no, PMDA: no
Description: mRNA-1273 at a dose of 100 μg
Study: 35127778
Drug: DHA algae
Approvals — FDA: no, EMA: no, PMDA: no
Description: DHA algae oil supplement (3.15 g daily for 6 months)
Study: 35128365
Drug: Sayana Press
Normalized name: garden cress sprout extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sayana Press injected every 4 months (3 treatment cycles) for 12 months
Study: 35128529
Drug: High-dose split-virus
Normalized name: influenza A virus (H1N1) antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose split-virus influenza vaccine (HD-SVV)
Study: 35128529
Drug: Standard dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard dose split-virus influenza vaccine (SD-SVV)
Study: 35128939
Drug: Extrafine Beclomethasone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extrafine Beclomethasone Dipropionate/Formoterol Fumarate/Glycopyrronium Bromide; specific dosage and duration not mentioned
Study: 35129069
Drug: Gamitrinib, a
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gamitrinib, a mitochondria-targeted small molecule Hsp90 inhibitor
Study: 35129214
Drug: Diazepam (3-day
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diazepam (3-day treatment)
Study: 37063970
Drug: Ticagrelor monotherapy
Normalized name: Ticagrelor
DrugBank: Ticagrelor (DB08816)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ticagrelor monotherapy after 3-month dual antiplatelet therapy (DAPT)
Study: 35129374
Drug: Once-daily oral
Normalized name: GEMTESA 75 MG Once-Daily Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once-daily oral cabotegravir 30 mg for 4 weeks
Study: 35129374
Drug: Five 600-mg
Normalized name: HISTA-FIVE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Five 600-mg (3-mL) intramuscular cabotegravir LA injections at weeks 5, 9, 17, 25, and 33
Study: 35129374
Drug: Daily oral
Normalized name: GEMTESA 75 MG Once-Daily Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily oral standard-of-care
Study: 35129472
Drug: Intrathoracic implantation
Normalized name: INVESTIGATIONAL ANTI-NEOPLASTIC DRUGS INTRATHORACIC ORGANS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intrathoracic implantation of multidrug-eluting microdevices (IMDs) containing 12 chemotherapeutic agents, inserted intraoperatively and retrieved with the resected specimen.
Study: 35129803
Drug: Ocrelizumab infusion
Normalized name: Ocrelizumab
DrugBank: Ocrelizumab (DB11988)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Ocrelizumab infusion after first-line immunotherapy
Study: 35130292
Drug: Treatment for
Normalized name: Hair Regrowth Treatment For Men
DrugBank: Minoxidil (DB00350)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Treatment for acute leukaemia during pregnancy; specific details on dosage and duration not available.
Study: 35130292
Drug: Successful treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Successful treatment of acute leukaemia prior to pregnancy; specific details on treatment not available.
Study: 35130417
Drug: Chemotherapy maintenance
Normalized name: Dental Resources Perio Maintenance Rinse
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy maintenance
Study: 35130417
Drug: Chemotherapy maintenance
Normalized name: Dental Resources Perio Maintenance Rinse
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy maintenance for hormone receptor-positive MBC patients
Study: 35130417
Drug: Endocrine therapy
Normalized name: ENDOCRINE THERAPY
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endocrine therapy maintenance for hormone receptor-positive MBC patients
Study: 35130417
Drug: Chemotherapy vs
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy vs Endocrine therapy maintenance
Study: 35130943
Drug: Trametinib 2
Normalized name: trametinib 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trametinib 2 mg QD in Mild HD patients
Study: 35130943
Drug: Trametinib 1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trametinib 1.5 mg QD in Moderate HD patients
Study: 35130943
Drug: Trametinib 1
Normalized name: trametinib 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trametinib 1 mg QD in Severe HD patients
Study: 35130943
Drug: Trametinib (various
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trametinib (various doses)
Study: 35131031
Drug: Assessment of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Assessment of anti-S1/S2 antibody titer, IL-6, and CRP levels.
Study: 35131040
Drug: Niraparib 300
Normalized name: niraparib 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Niraparib 300 mg orally once daily until treatment discontinuation, death, or study termination.
Study: 35131254
Drug: Topical ruxolitinib
Normalized name: ruxolitinib Topical Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical ruxolitinib applied twice daily for 8 weeks
Study: 35131513
Drug: Direct oral
Normalized name: direct blue 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Direct oral challenge for penicillin allergy delabeling
Study: 35131875
Drug: PCA062 at
Normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
Approvals — FDA: no, EMA: no, PMDA: no
Description: PCA062 at 3.6 mg/kg every 2 weeks
Study: 35131875
Drug: PCA062 at
Normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
Approvals — FDA: no, EMA: no, PMDA: no
Description: PCA062 at various dose levels (0.4 to 5.0 mg/kg every 2 weeks)
Study: 35131903
Drug: Olaparib maintenance
Normalized name: Olaparib
DrugBank: Olaparib (DB09074)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Olaparib maintenance monotherapy (300 mg orally twice daily until disease progression or unacceptable toxicity)
Study: 35131903
Drug: Olaparib maintenance
Normalized name: Olaparib
DrugBank: Olaparib (DB09074)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Olaparib maintenance monotherapy
Study: 35132704
Drug: Lanreotide autogel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lanreotide autogel (LAN) 120 mg/28 days for 1 year
Study: 35133604
Drug: Patients without
Normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients without previous psychiatric treatment
Study: 35133636
Drug: Aclidinium/formoterol 400/12
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aclidinium/formoterol 400/12 µg twice daily